CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 106 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Losartan 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00720226
NCT00720226Phase 4Completed
CompareCT.gov

Efficacy of Losartan in Preventing Progression of COPD

Johns Hopkins University·interventional·Posted Jul 22, 2008·Updated Apr 25, 2017

In Brief

A Phase 4 clinical trial evaluating Losartan and Placebo for COPD and 3 related conditions. Completed, enrolled 106 participants across 1 site.

Detailed Summary

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, Emphysema, Chronic Bronchitis, Smoking
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Merck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2008
Enrollment StartJul 1, 2008
Primary CompletionAug 1, 2014
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 17.9 years ago

Interventions

Losartandrug

Losartan 100 mg daily

Placebodrug

Placebo pill daily